Flamel Technologies' NDA for Bloxiverz gets FDA nod

06/4/2013 | RTT News

The FDA has granted Flamel Technologies approval for its new drug application for Bloxiverz. The drug is used to reverse the effects of non-depolarizing neuromuscular blocking agents following surgery.

View Full Article in:

RTT News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Executive Officer
CarePoint Health Plan
Jersey City, NJ
Regional Director, Southeastern Region - State Affairs
America's Heatlh Insurance Plans (AHIP)
Washington, DC
Assistant General Counsel
Cardinal Health
Columbus, OH
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC